首页> 外文期刊>Human vaccines & immunotherapeutics. >Cross-neutralization of antibodies induced by vaccination with Purified Chick Embryo Cell Vaccine (PCECV) against different Lyssavirus species
【24h】

Cross-neutralization of antibodies induced by vaccination with Purified Chick Embryo Cell Vaccine (PCECV) against different Lyssavirus species

机译:纯化小鸡胚细胞疫苗(PCECV)疫苗接种后针对不同狂犬病病毒种的抗体的交叉中和作用

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Rabies is a neglected zoonotic disease caused by viruses belonging to the genus lyssavirus. In endemic countries of Asia and Africa, where the majority of the estimated 60,000 human rabies deaths occur, it is mainly caused by the classical rabies virus (RABV) transmitted by dogs. Over the last decade new species within the genus lyssavirus have been identified. Meanwhile 15 (proposed or classified) species exist, including Australian bat lyssavirus (ABLV), European bat lyssavirus (EBLV-1 and -2), Duvenhage virus (DUVV), as well as Lagos bat virus (LBV) and Mokola virus (MOKV) and recently identified novel species like Bokeloh bat lyssavirus (BBLV), Ikoma bat lyssavirus (IKOV) or Lleida bat lyssavirus (LLBV). The majority of these lyssavirus species are found in bat reservoirs and some have caused human infection and deaths. Previous work has demonstrated that Purified Chick Embryo Cell Rabies Vaccine (PCECV) not only induces immune responses against classical RABV, but also elicits cross-neutralizing antibodies against ABLV, EBLV-1 and EBLV-2.Material & Methods: Using the same serum samples as in our previous study, this study extension investigated cross-neutralizing activities of serum antibodies measured by rapid fluorescent focus inhibition test (RFFIT) against selected other non-classical lyssavirus species of interest, namely DUVV and BBLV, as well as MOKV and LBV.Results: Antibodies developed after vaccination with PCECV have neutralizing capability against BBLV and DUVV in the same range as against ABLV and EBLV-1 and -2. As expected, for the phylogenetically more distant species LBV no cross-neutralizing activity was found. Interestingly, 15 of 94 serum samples (16%) with a positive neutralizing antibody titer against RABV displayed specific cross-neutralizing activity (65-fold lower than against RABV) against one specific MOKV strain (Ethiopia isolate), which was not seen against a different strain (Nigeria isolate).Conclusion: Cross-neutralizing activities partly correlate with the phylogenetic distance of the virus species. Cross-neutralizing activities against the species BBLV and DUVV of phylogroup 1 were demonstrated, in line with previous results of cross-neutralizing activities against ABLV and EBLV-1 and -2. Potential partial cross-neutralizing activities against more distant lyssavirus species like selected MOKV strains need further research.
机译:背景:狂犬病是一种由狂犬病病毒属病毒引起的被忽视的人畜共患病。在亚洲和非洲的流行国家中,估计有60,000人的狂犬病死亡多数发生,这主要是由狗传播的经典狂犬病病毒(RABV)引起的。在过去的十年中,已经确定了狂犬病病毒属中的新物种。同时存在15个(提议或分类的)物种,包括澳大利亚蝙蝠狂犬病病毒(ABLV),欧洲蝙蝠狂犬病病毒(EBLV-1和-2),Duvenhage病毒(DUVV)以及拉各斯蝙蝠病毒(LBV)和莫科拉病毒(MOKV) ),最近发现了新物种,例如Bokeloh蝙蝠狂犬病病毒(BBLV),Ikoma蝙蝠狂犬病病毒(IKOV)或Lleida蝙蝠狂犬病病毒(LLBV)。这些狂犬病病毒大多数是在蝙蝠库中发现的,有些已经引起人类感染和死亡。先前的研究表明,纯化的小鸡胚胎细胞狂犬病疫苗(PCECV)不仅可以诱导针对经典RABV的免疫反应,还可以引发针对ABLV,EBLV-1和EBLV-2的交叉中和抗体。材料与方法:使用相同的血清样品与我们以前的研究一样,本研究扩展了针对快速发展的快速荧光聚焦抑制试验(RFFIT)对选定的其他非典型狂犬病病毒,即DUVV和BBLV以及MOKV和LBV的血清抗体的交叉中和活性。结果:接种PCECV疫苗后开发的抗体对BBLV和DUVV的中和能力与针对ABLV和EBLV-1和-2的范围相同。如所期望的,对于在系统发育上更远的物种LBV,没有发现交叉中和活性。有趣的是,在针对RABV的中和抗体滴度为阳性的94个血清样本中,有15个(16%)对一种特定的MOKV菌株(埃塞俄比亚分离株)表现出了特定的交叉中和活性(比针对RABV的抗氧化能力低65倍),而针对一种抗结论:交叉中和活性部分与病毒种类的系统发育距离有关。证明了对phylogroup 1物种BBLV和DUVV的交叉中和活性,这与先前对ABLV和EBLV-1和-2的交叉中和活性的结果一致。针对更远距离的狂犬病病毒(如选定的MOKV株)的潜在的部分交叉中和活性需要进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号